Description
Scope of the Report The report titled“ Global Glaucoma Treatment Market: Trends and Opportunities( 2015 Edition)” analyzes the potential opportunities, challenges, demand drivers and significant trends representing the Glaucoma treatment market. The report elucidates facts on the glaucoma treatment market as supplemented by the latest available statistics. It also profiles and analyzes the leading four companies operating in this industry with latest data and a brief overview of their business and financial performance along with a brief discussion of their future business strategies. The report gives valuable insight into technology used in glaucoma treatment market, its demand in various geographies. In the report, we also try to study the growth pattern in the prescriptions and revenue earned by the glaucoma treatment companies and the latest trends concerning glaucoma treatment market. Most importantly, we have analyzed the current market size and project future market size of the overall glaucoma treatment market for the years to come.
Request a sample of this report @ http:// www. orbisresearch. com / contacts / request-sample / 185298.
Company Coverage Biolite Israeli Pfizer Inc. Merck & Co. Inc. Alcon( A division of Novartis)
Products Covered Prostaglandin Combination Market Carbonic Anhydrase Inhibitor Beta Blocker Alpha Agonist & Cholinergic Surgical Devices
Purchase a copy of Global Glaucoma Treatment Market visit @ http:// www. orbisresearch. com / contact / purchase / 185298 For more information contact sales @ orbisresearch. com.
Executive Summary The global Glaucoma market has been growing rapidly since the past several years mainly due to innovation such as introduction of IOPtiMa, OTP-TX, anti-VEGF therapy, photodynamic therapy( PDT) laser photocoagulation, Rhopressa, latanoprost and Vesneo. Among the several varieties of drugs and surgeries available in the market, the demand for drugs such as Prostaglandins which includes Trabatan, Lumbigan are the highest due to its high efficiency in treating glaucoma. Vesneo has shown a superior intraocular pressure reduction effect on beta-blocker timolol, the most widely used comparator in registration trials for glaucoma, in two phase 3 studies.
www. orbisresearch. com; + 1( 214) 884-6817; + 9120-64101019